• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Korlym (mifepristone)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Korlym (mifepristone)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Korlym (mifepristone) is a small-molecule progesterone and glucocorticoid antagonist. It blocks the binding of cortisol to its receptor. It does not decrease cortisol production but reduces the effects of excess cortisol, such as high blood sugar levels.

    Korlym was specifically approved to control hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome who have type II diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

    Korlym is supplied as a tablet for oral administration. The recommended initial dose is a single dose of 300 mg orally once daily. The daily dose of Korlym may be increased in 300 mg increments. The dose of Korlym may be increased to a maximum of 1200 mg once daily but should not exceed 20 mg/kg per day. Increases in dose should not occur more frequently than once every 2-4 weeks.

    Clinical Results

    FDA Approval
    The FDA approval of Korlym was based on an uncontrolled, open-label, 24-week, multicenter clinical study. The study enrolled 50 subjects with clinical and biochemical evidence of hypercortisolemia despite prior surgical treatment and radiotherapy. The subjects were placed in one of two cohorts: a diabetes cohort and a hypertension cohort and were evaluated separately. Korlym treatment was started at a dose of 300 mg once a day. The study protocol allowed an increase in dose to 600 mg after two weeks, and then by additional 300 mg increments every four weeks to a maximum of 900 mg per day for patients <60 kg, or 1200 mg per day for patients >60 kg.
    Diabetes Cohort
    The primary efficacy analysis for the diabetes cohort was an analysis of responders. A responder was defined as a subject who had a ≥25% reduction from baseline in glucose AUC. Fifteen of 25 subjects (60%) were treatment responders.
    Hypertension Cohort
    There were no changes in mean systolic and diastolic blood pressures at the end of the trial relative to baseline.

    Side Effects

    Adverse events associated with the use of Korlym may include, but are not limited to, the following:

    • nausea
    • fatigue
    • headache
    • decreased blood potassium
    • arthralgia
    • vomiting
    • peripheral edema
    • hypertension
    • dizziness
    • decreased appetite
    • endometrial hypertrophy

    Mechanism of Action

    Korlym (mifepristone) is a small-molecule progesterone and glucocorticoid antagonist. It is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor. In addition, mifepristone appears to have little or no affinity for estrogen, muscarinic, histaminic, or monoamine receptors.

    Additional Information

    For additional information regarding Korlym or hyperglycemia in adults with endogenous Cushing’s syndrome, please visit the Corcept web page.

    Approval Date: 2012-02-01
    Company Name: Corcept Therapeutics
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing